Loading market dashboard
Bicara Therapeutics Inc. Common Stock
BCAXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer.
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Bicara Therapeutics NASDAQ: BCAX said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference.
Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara's 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara's Chief Commercial Officer.
Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript
Bicara Therapeutics NASDAQ: BCAX said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while reporting a strengthened cash position following a February public offering.
Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026
This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.
Bicara Therapeutics Inc. (NASDAQ: BCAX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $21.63 and last traded at $20.85, with a volume of 552051 shares trading hands. The stock had previously closed at $21.47. Analyst Ratings Changes A number of equities analysts
BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on April 1, 2026 to one new employee under Bicara's 2026 Inducement Plan as a material inducement to employment.
Shares of Bicara Therapeutics Inc. (NASDAQ: BCAX - Get Free Report) reached a new 52-week high on Wednesday after The Goldman Sachs Group raised their price target on the stock from $14.00 to $16.00. The Goldman Sachs Group currently has a neutral rating on the stock. Bicara Therapeutics traded as high as $21.05 and last traded
The average of price targets set by Wall Street analysts indicates a potential upside of 54.9% in Bicara Therapeutics Inc. (BCAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Bicara Therapeutics Inc. maintains a Buy rating, driven by progress in its pivotal phase 3 FORTIFI-HN01 study for 1st-line R/M HPV-negative HNSCC. BCAX's ficerafusp alfa plus KEYTRUDA achieved a 12-month OS of 61% and a confirmed ORR of 54% in phase 1/1b, supporting continued development. Key upcoming catalysts for BCAX include phase 3 interim data in mid-2027 and long-term phase 1b follow-up at ASCO 2026, with near-full enrollment expected by year-end.
Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript
CEO Claire Mazumdar sold 8,234 common shares for ~$154,000 between March 4 and March 6, 2026, at a weighted average price around $18.74 per share. The transaction represented 2.37% of Mazumdar's direct common stock holdings, reducing direct ownership to 339,392 shares.
Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading and every-three-week maintenance dose of ficerafusp alfa Corporate call to discuss financial results and business updates on Monday, March 30, 2026 at 8:30 a.m. ET BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update.
8,234 shares were sold for a transaction value of ~$154,000, with weighted average pricing around $18.74 per share on March 4–6, 2026. This sale reduced Mazumdar's direct Common Stock holdings to 339,392 shares post-transaction.
Bank of America has initiated coverage of Bicara Therapeutics (NASDAQ:BCAX) with a “Buy” rating and a $35 price objective, citing the potential of its lead drug candidate to reshape first-line treatment for a form of head and neck cancer, according to a research note published Tuesday. The analysts pointed to the company's lead asset ficerafusp alfa (ficera) as the central driver of their outlook.
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day.
Bicara Therapeutics Inc. (NASDAQ: BCAX - Get Free Report) CEO Claire Mazumdar sold 1,596 shares of the stock in a transaction on Friday, March 20th. The shares were sold at an average price of $18.95, for a total value of $30,244.20. Following the transaction, the chief executive officer directly owned 339,392 shares of the company's stock,
Bicara Therapeutics Inc. (BCAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Bicara Therapeutics (NASDAQ: BCAX) outlined its clinical and development strategy for its lead bifunctional antibody program, FICERA, during a presentation and fireside chat at TD Cowen's 46th annual health care conference. Ryan Cohlhepp, the company's President and COO, said the company is advancing FICERA-an EGFR and TGF-beta bifunctional-into a pivotal study in frontline HPV-negative recurrent/metastatic head
